Anxiety disorders clinical trials, in English

Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).

NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. this study wants to understand the brain mechanisms that produce fear and anxiety in humans.

NCT05120635 · Official ClinicalTrials.gov record · Duke University

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study evaluating the how well it works, safety, and tolerability of ITI-1284 compared with dummy treatment (placebo) as added on top of your current treatment therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

NCT06480383 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to assess the how well it works, safety, and tolerability of ITI-1284 as this drug alone treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.

NCT06701903 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

The main objective of this randomly assigned clinical trial is to study if various modalities of brief (eight sessions) and ultra-brief (four sessions) transdiagnostic cognitive-behavioral treatment work for decrease emotional symptoms and disorders, as well as to find out which emotional regulation processes and common factor of the intervention itself are involved in the therapeutic improvement. The investigators will compare the interventions of four groups: ultra-brief group treatment (1), brief group treatment (2), ultra-brief individual treatment (3) with the ultra-brief relaxation (control) group.

NCT06909669 · Official ClinicalTrials.gov record · Universidad de Córdoba

This study wants to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations.

NCT06934525 · Official ClinicalTrials.gov record · Bradley Hospital

This Phase 2a clinical trial is designed to measure the safety, tolerability, and preliminary how well it works of a 3 mg dose of psilocybin oral solution for the treatment of Generalized Anxiety Disorder (GAD). The study consists of three sequential phases: Screening Phase (up to 4 weeks), Open-label Run-in Phase (4 weeks), neither you nor the study doctors know who gets the real treatment Treatment Phase (4 weeks) Screening Phase During the Screening Visit, participants will provide informed consent and undergo a comprehensive medical evaluation, including an abbreviated psychiatric assessment, to determine eligibility.

NCT06969170 · Official ClinicalTrials.gov record · Claudio N Soares

This randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with dummy treatment (placebo).

NCT07123467 · Official ClinicalTrials.gov record · Wayne State University

Some adolescents experience periods of anxiety and/or depression, and some find that these periods return over time. this study wants to examine whether digital interventions-where individuals work systematically with their own thoughts and feelings during periods when they feel well-can help them maintain well-being for longer.

NCT07346911 · Official ClinicalTrials.gov record · University of Oslo

This is a qualitative study of participants who have taken part in a randomly assigned controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.

NCT07382323 · Official ClinicalTrials.gov record · Karolinska Institutet

This study aims to measure the clinical how well it works and safety of electroacupuncture (EA) as an added on top of your current treatment treatment for generalized anxiety disorder (GAD). Participants in the clinical trial will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group.

NCT07392645 · Official ClinicalTrials.gov record · Lishu Gao

The goal of this clinical trial is to measure the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are: * Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?

NCT07458100 · Official ClinicalTrials.gov record · Peking University

This study wants to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to dummy treatment (placebo).

NCT07489651 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc

Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and 2021.

NCT07618208 · Official ClinicalTrials.gov record · Assistance Publique - Hôpitaux de Paris

A proof of concept case study to investigate accelerated LIFU protocol in chronic pain and anxiety populations.

NCT07686354 · Official ClinicalTrials.gov record · Virginia Polytechnic Institute and State University

This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders. Specifically, it examines whether Expectancy Focused Exposure (EFE), based on the inhibitory learning model, is more effective than Anxiety Focused Exposure (AFE) in reducing anxiety symptoms and preventing the return of fear over time.

NCT07753330 · Official ClinicalTrials.gov record · University of Chile

This is a global, phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, 3-arm, compared with a dummy treatment, multicenter study designed to compare the how well it works, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per day \[mg/day\]) to dummy treatment (placebo) in adults at least 18 years of age with generalized anxiety disorder (GAD) over 8 weeks.

NCT07759128 · Official ClinicalTrials.gov record · Otsuka Pharmaceutical Development & Commercialization, Inc.

This is a global, phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, 2-arm, dummy treatment (placebo) controlled, multicenter trial designed to compare the how well it works, whether it is safe and how hard side effects are to live with of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to dummy treatment (placebo) over an 8-week neither you nor the study doctors know who gets the real treatment treatment period in adults with generalized anxiety disorder (GAD).

NCT07767903 · Official ClinicalTrials.gov record · Otsuka Pharmaceutical Development & Commercialization, Inc.

This randomly assigned, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD). you would be randomly assigned in a 1:1 ratio to receive cTBS targeting either the right posterior parietal cortex (R-PPC) or the right dorsolateral prefrontal cortex (R-DLPFC).

NCT07770919 · Official ClinicalTrials.gov record · Military Hospital 175

The purposes of this study are: (1) to identify baseline predictors of relative success in cognitive, behavioral, and mindfulness-based treatments for anxiety, (2) explore who benefits from a brief, video-based skill training compared to receiving 4 sessions of therapy, and (3) to evaluate how durable these effects are over 1 year.

NCT07774481 · Official ClinicalTrials.gov record · Ohio State University

This is a global, Phase 3, multicenter, open-label extension trial designed to measure the long-term safety, tolerability and how well it works of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.

NCT07786454 · Official ClinicalTrials.gov record · Otsuka Pharmaceutical Development & Commercialization, Inc.

This study will evaluate whether Solution-Focused Therapy (SFT) helps reduce symptoms of Generalized Anxiety Disorder (GAD) in emerging adults in Pakistan. Participants will first be screened to identify those with mild to moderate levels of GAD.

NCT07798063 · Official ClinicalTrials.gov record · International Islamic University, Islamabad

This study wants to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded to treatment previously. GAD is a mental health condition defined by constant, uncontrollable worry about everyday things that lasts for six months or more.

NCT07807865 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD). The main questions it aims to answer are: Does the accelerated treatment protocol using the BTL-699-2 device reduce self-reported anxiety symptoms (as measured by the GAD-7 scale) 3 months after the final treatment?

NCT07819773 · Official ClinicalTrials.gov record · BTL Industries Ltd.

This prospective, single-arm, watch-and-measure (no experimental treatment required) pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care. Adult patients complete a self-report assessment before a routine primary care visit.

NCT07834684 · Official ClinicalTrials.gov record · Singula Health, Inc.

This study wants to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to dummy treatment (placebo) when given as an additional (added on top of your current treatment) therapy in participants with generalized anxiety disorder (GAD; a mental health condition defined by uncontrollable, and excessive worry about everyday events for a long period of time).

NCT07856420 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

This study aims to understand how anxiety disorders, depressive disorders, and bipolar disorder change over time and to identify patterns that may help with earlier recognition, diagnosis, and prediction of future symptoms. The study will enroll approximately 2,690 participants aged 12 to 55 years across multiple hospitals in China.

NCT07903246 · Official ClinicalTrials.gov record · Second Affiliated Hospital, Zhejiang University, School of Medicine

This study will compare inspiratory muscle training and diaphragmatic breathing exercises in individuals with generalized anxiety disorder (GAD). It aims to see if adding either breathing-based intervention to a combined exercise program improves anxiety symptoms and other health-related outcomes compared with adding progressive muscle relaxation.

NCT07913503 · Official ClinicalTrials.gov record · Saglik Bilimleri Universitesi